Viewing Information

Getting Started

Read all the information presented below. When ready select the "View Program" tab above.

Claiming CE Credit

To receive credits, participants must review the program materials in their entirety and complete the online post examination and evaluation. CE credits require a post examination score of 80% or higher.

Program Summary

While gadolinium-based contrast agents (GBCAs) are essential to performing MR imaging, guidance from the US Food and Drug Administration (FDA) and the American College of Radiology (ACR) includes the recommendation of limiting a patient's gadolinium exposure. One technique for reducing gadolinium exposure is to use a high-relaxivity gadolinium-based contrast agent (GBCA) that can be administered at a lower dose than a conventional GBCA without negatively impacting image quality. Gadopiclenol is an FDA-approved, macrocyclic, high relaxivity GBCA that reveals high-quality images at half the conventional dose of other GBCAs and is approved for body MRI applications.

This educational program provides the clinical rationale for adopting the use of Gadopiclenol for Body MRI.

Through case study reviews, Bachir Taouli MD, will share clinical insights to achieve optimal image quality using a lower administered gadolinium dose during body MRI. A focus on the safety, selection and utilization of a high relaxivity, lower dose GBCA will be supported by clinical evidence and imaging protocols. Audience participation will be encouraged during the Q & A session following the presentation.

Effective Date: January 14, 2025
Expiration Date: February 29, 2028
Format: Self Instructional - Audio Visual with Slides
Educational Credits:
One (1.0) ARRT Category A CE Credits
One (1.0) AHRA CRA Credits
Estimated Completion Time: 60 minutes

This webinar is an educational activity sponsored by Guerbet, LLC.

Target Audience & Cost

This program is intended for: Radiologic Technologists, Radiology Administrators and related Imaging Professionals.

There is no cost to participate in this program.

Educational Objectives

Upon completion of this CE activity the healthcare provider should be able to:

• State the properties of the FDA-approved GBCAs (gadolinium-based contrast agents).
• Understand the clinical risks and safety considerations of GBCA selection and utilization.
• Implement the use of Gadopiclenol in Body MRI applications.

Presented by

Bachir Taouli, MD MHA

Director of Body MRI and Cancer Imaging Program
Vice-chair of Translational Research
Department of Diagnostic, Molecular and Interventional Radiology
BioMedical Engineering and Imaging Institute
Icahn School of Medicine at Mount Sinai, New York

Bachir Taouli, MD, MS, is a Professor of Radiology in the Abdominal Imaging/Body MRI Section in the Department of Diagnostic, Molecular and Interventional Radiology, and the BioMedical Engineering and Imaging Institute (BMEII) at the Icahn School of Medicine at Mount Sinai in New York. He is also the director of Body MRI and Cancer Imaging Core in the Department of Radiology and BMEII and Vice-Chair for translational research in the Department of Radiology.

Dr. Taouli is also a clinician scientist with expertise in advanced MRI of the abdomen and pelvis and directs the Body MRI quantitative group at BMEII. He was named “Distinguished Investigator” of the Academy of Radiology Research, Fellow of the ISMRM (The International Society for Magnetic Resonance in Medicine), SAR (Society of Abdominal Radiology), ICIS (International Cancer Imaging Society) and SABI (Society of Advanced Body Imaging). He has authored over 270 peer-reviewed manuscripts mostly on Body MRI, and have mentored several students, residents, fellows and postdocs for research.

Accreditation

Radiologic Technologists:
This course meets all criteria and has been approved by the AHRA, The Association for Medical Imaging Management for one (1.0) ARRT Category A CE Credit.

Radiology Administrators:
This course meets all CRA renewal credit criteria and has been approved for one (1.0) continuing education credit in the following CRA domain: Operations Management (OM).

For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board or other credentialing organization.

Method of Participation/Criteria for Success

CE Credits
To receive CE credits for participating in this CE activity you must successfully complete the online post examination with a passing score of 80% or higher.

Online examinations return an immediate grade report. Upon receiving a passing score click Continue and complete the evaluation form. To view and print your Statement of Credit click the Print/View Certificate button displayed from within your MyAR Archives page.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

• Risk Associated with Intrathecal Use: Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures. The safety and effectiveness of ELUCIREM have not been established with intrathecal use. ELUCIREM is not approved for intrathecal use.
• Nephrogenic Systemic Fibrosis: GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of ELUCIREM among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities.
• Hypersensitivity Reactions: With GBCAs, serious hypersensitivity reactions have occurred. Before ELUCIREM administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to ELUCIREM.
• Gadolinium Retention: Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by other organs (e.g. brain, skin, kidney, liver, and spleen). While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Minimize repetitive GBCA imaging studies, particularly closely spaced studies when possible.
• Acute Kidney Injury: In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent.
• Extravasation and Injection Site Reactions: Injection site reactions such as injection site pain have been reported in the clinical studies with ELUCIREM. Extravasation during ELUCIREM administration may result in tissue irritation. Ensure catheter and venous patency before the injection of ELUCIREM.
• Interference with Visualization of Lesions Visible with Non-Contrast MRI: As with any GBCA, ELUCIREM may impair the visualization of lesions seen on non-contrast MRI.

• Pregnancy: GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. There are no available data on ELUCIREM use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.
• Lactation: There are no data on the presence of ELUCIREM in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is excreted in breast milk.
• Pediatric Use: The safety and effectiveness of ELUCIREM have not been established in pediatric patients younger than 2 years of age.
• Geriatric Use: This drug is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function.
• Renal Impairment: In patients with renal impairment, the exposure of gadopiclenol is increased compared to patients with normal renal function. This may increase the risk of adverse reactions such as NSF. No dose adjustment of ELUCIREM is recommended for patients with renal impairment.